IN8bio Inc. (INAB)
INAB trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$1.18
-4.07% on the day
Market cap
$11.6M
Nano cap
Revenue
Not reported in SEC XBRL data
Net income
Not reported in SEC XBRL data
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | INAB on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001740279 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials
Not reported in SEC XBRL data.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-06-01 |
| Latest annual report | 10-K | 2026-03-12 |
| Latest quarterly / interim | 10-Q | 2026-08-06 |
| Latest current report | 8-K | 2026-08-06 |
| Latest proxy | DEFA14A | 2026-03-26 |
Source: SEC EDGAR submissions feed, 410 recent filings. All filings on EDGAR.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| INTS | Intensity Therapeutics Inc. | $3.55 | +7.25% | $11.6M |
| PASG | Passage Bio Inc. | $3.64 | -20.00% | $11.7M |
| PLUR | Pluri Inc. | $0.9400 | -3.08% | $11.9M |
| ESLA | Estrella Immunopharma Inc. | $0.3140 | -4.44% | $13.7M |
| TCRX | TScan Therapeutics Inc. | $0.2167 | -8.91% | $13.8M |
| BCDA | BioCardia Inc. | $0.9903 | -2.91% | $15.0M |
| JSPR | Jasper Therapeutics Inc. | $0.4956 | -10.70% | $16.5M |
| DYAI | Dyadic International Inc. | $0.4253 | +1.00% | $17.0M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier